Analysis of dal-OUTCOMES included @,@ patients ( @ % statin-treated ) randomly assigned @ to @ weeks after ACS to treatment with dalcetrapib ( a cholesteryl ester transfer protein inhibitor ) or placebo and followed for a median @ months .